Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience.

Drugs R D · 2012 · PMC3585834 · PMID 23199211

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significancep = 0.22not close (p > 0.1)

a notable trendno p-value reported

There was a notable trend toward longer OS in female patients (22.76 months) than in male patients (13.42 months), but the difference did not reach statistical significance (p = 0.22).

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.